We’re currently upgrading our membership platform to bring you an improved experience. During this transition, access to member accounts is temporarily unavailable. We appreciate your patience and can’t wait to share the new and improved system with you soon!
For urgent membership questions, please contact info@clpsychiatry.org.
Journal Article Annotations
2024, 2nd Quarter
Annotations by Liliya Gershengoren, MD
July, 2024
The finding:
Ketamine and esketamine were shown to significantly reduce post-partum depression incidence and Edinburgh Postnatal Depression Scale (EPDS) scores. Higher dosages and patient-controlled intravenous analgesia (PCIA) methods were also particularly effective. However, the use of ketamine and esketamine also led to increased short-term adverse effects such as dizziness, diplopia, hallucination, and headache.
Strength and weaknesses:
The study’s strengths include a thorough analysis that combined data from 14 different studies, involving 2916 patients, which provides strong evidence that ketamine and esketamine can help prevent postpartum depression (PPD). The authors also conducted subgroup analyses to identify specific factors that enhance treatment efficacy, such as dosage and administration method. However, a notable weakness is the predominance of studies conducted in China, which may limit the generalizability of the findings to other populations. Additionally, the study reported considerable heterogeneity among the included studies, potentially affecting the reliability of the overall conclusions.
Relevance:
This study provides robust evidence supporting the use of ketamine and esketamine to prevent postpartum depression (PPD) in patients undergoing cesarean deliveries. As a result, the study offers practical insights for clinical interventions aimed at reducing PPD incidence. Additionally, understanding the associated short-term side effects can help psychiatrists weigh the benefits and risks when considering these treatments for their patients.